Who are Non-steroidal aromatase inhibitor therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kisqali, Aromasin, Femara, LETROZOLE, Arimidex, ANASTROZOLE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/non-steroidal-aromatase-inhibitor-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Non-steroidal aromatase inhibitor therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-steroidal aromatase inhibitor therapy (Non-steroidal aromatase inhibitor therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase inhibitor. Area: Oncology.

phase 3 Aromatase inhibitor Aromatase (CYP19A1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Non-steroidal aromatase inhibitor therapy (Non-steroidal aromatase inhibitor therapy) — Amgen. A non-steroidal aromatase inhibitor blocks the enzyme aromatase to reduce estrogen production in postmenopausal women with hormone receptor-positive breast cancer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Non-steroidal aromatase inhibitor therapy TARGET	Non-steroidal aromatase inhibitor therapy	Amgen	phase 3	Aromatase inhibitor	Aromatase (CYP19A1)
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
Aromasin	exemestane	Pfizer	marketed	Aromatase Inhibitor [EPC]	Aromatase	1999-01-01
Femara	letrozole	Novartis AG	marketed	Aromatase Inhibitor [EPC]	aromatase enzyme	1997-07-25
LETROZOLE	LETROZOLE		marketed	Aromatase Inhibitor [EPC]		1997-01-01
Arimidex	anastrozole	AstraZeneca	marketed	Aromatase inhibitor	Aromatase enzyme	1995-12-27
ANASTROZOLE	ANASTROZOLE		marketed	Aromatase Inhibitor [EPC]	aromatase	1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase inhibitor class)

AstraZeneca · 4 drugs in this class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 2 drugs in this class
Eastern Virginia Medical School · 1 drug in this class
Genor Biopharma Co., Ltd. · 1 drug in this class
Gynaecologisch Oncologisch Centrum Zuid · 1 drug in this class
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · 1 drug in this class
IVI Madrid · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Lumara Health, Inc. · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Non-steroidal aromatase inhibitor therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/non-steroidal-aromatase-inhibitor-therapy. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab